focu
place
pharmaceut
biomed
applic
novel
claydrug
hybrid
materi
categor
method
administr
clay
miner
use
mani
year
pharmaceut
medicin
ingredi
therapeut
purpos
number
studi
attempt
explor
claydrug
hybrid
materi
biomed
applic
desir
function
sustain
releas
increas
solubl
enhanc
adsorpt
mucoadhes
biocompat
target
etc
present
review
attempt
summar
stateoftheart
claydrug
hybrid
materi
advantag
depend
method
administr
also
deal
challeng
futur
perspect
clay
mineralbas
hybrid
biomed
applic
much
attent
paid
clay
miner
sinc
earli
day
humankind
variou
purpos
abund
natur
inexpens
uniqu
structur
properti
carretero
choy
et
al
clay
miner
gener
hydrat
aluminosil
contain
alkalin
alkalin
earth
metal
among
layer
clay
miner
phyllosil
includ
kaolin
talc
sensu
lato
smectit
fibrou
clay
use
excipi
formul
differ
dosag
form
solid
liquid
semisolid
applic
clay
miner
determin
individu
intrins
properti
deriv
structur
type
layer
type
chemic
composit
kaolin
group
miner
includ
kaolinit
kln
halloysit
layertyp
structur
layer
compos
tetrahedr
silica
sheet
octahedr
alumina
sheet
combin
unit
layer
stack
along
c
axi
hydrogen
bond
interact
although
kln
also
rel
small
specif
surfac
area
ssa
compar
type
clay
miner
report
dealt
rapid
rate
exchang
reaction
good
adsorpt
properti
surfac
small
molecul
protein
bacteria
virus
barral
et
al
rutkai
f
talc
tlc
phyllosil
compos
edgelink
mgo
oh
octahedr
sheet
locat
two
cornerlink
tetrahedr
silica
sheet
share
oxygen
atom
talc
excel
adsorb
due
larg
adsorpt
capac
hydrophil
hydrophob
substanc
pez
galindo
et
al
rotenberg
et
al
jadhav
et
al
smectit
sme
expand
phyllosil
layer
charg
per
formula
unit
individu
layer
compos
sheet
octahedr
coordin
aluminum
magnesium
iron
atom
oxygen
ligand
hydroxyl
group
sandwich
two
sheet
tetrahedr
silicon
coordin
oxygen
atom
smectit
subdivid
dioctahedr
trioctahedr
sme
depend
number
natur
octahedr
cation
octahedr
andor
tetrahedr
coordin
element
substitut
cation
lower
valenc
mg
andor
al
respect
cation
exchang
capac
cec
develop
due
format
neg
layer
charg
distribut
upon
substitut
larg
cec
surfac
area
swellabl
also
biocompat
sme
recommend
frequent
biomed
applic
especi
pharmaceut
gamiz
et
al
aguzzi
et
al
park
et
al
palygorskit
sepiolit
phyllosil
unlik
clay
miner
fibrou
morpholog
contain
continu
twodimension
tetrahedr
sheet
differ
layer
silic
lack
continu
octahedr
sheet
consid
ribbon
phyllosil
structur
ribbon
link
next
ribbon
invers
sio
tetrahedra
along
set
bond
microns
needlelik
fibrou
clay
use
wide
adsorb
structur
contain
micropor
larg
ssa
g
compar
kaolinit
g
palygorskit
sepiolit
also
amen
assembl
polym
matrix
hydrogen
bond
make
suitabl
pharmaceut
formul
visera
pezgalindo
visera
properti
variou
type
clay
miner
make
suitabl
biomed
applic
abund
plenti
surfac
space
reactiv
mani
biolog
organ
inorgan
substanc
clay
miner
long
use
folk
remedi
variou
purpos
relief
diarrhea
blood
clot
wound
heal
etc
chang
et
al
william
et
al
li
et
al
alavi
et
al
exampl
peloid
mud
use
therapeut
administ
local
allevi
joint
pain
recov
bonemuscl
damag
slowli
elev
local
temperatur
underli
tissu
without
caus
damag
ferrand
yvon
cara
et
al
cara
et
al
medicin
clay
also
use
cure
ulcer
prevent
infect
even
treat
allergi
bodi
poensin
et
al
venial
et
al
moreov
clay
miner
adjust
improv
pharmaceut
properti
depend
medic
applic
requir
hydrophil
surfac
render
hydrophob
differ
treatment
includ
ion
exchang
quaternari
ammonium
compound
result
organoclay
compat
polym
use
prepar
organoclaypolym
composit
organoclay
either
individu
combin
polym
use
wide
formul
biomed
applic
ghadiri
et
al
new
organicinorgan
hybrid
materi
current
develop
biomed
applic
begin
clay
miner
combin
drug
intend
target
purpos
choy
et
al
choy
et
al
yang
et
al
choy
et
al
oh
et
al
kim
et
al
lim
et
al
wang
et
al
clay
miner
effici
safe
transport
may
provid
new
paradigm
field
drug
deliveri
system
dd
compar
inorgan
materi
aguzzi
et
al
suresh
et
al
visera
et
al
de
sousa
rodrigu
et
al
drug
deliveri
system
mani
advantag
eg
reduc
side
effect
drug
due
sustain
releas
better
patient
complianc
reduc
dose
frequenc
mani
type
controlledreleas
formul
immedi
upon
placement
releas
medium
larg
initi
bolu
drug
releas
uncontrol
reach
stabl
releas
rate
ie
initi
burst
burst
releas
result
toxic
drug
formul
control
releas
rate
drug
ie
delay
releas
extend
releas
sustain
releas
achiev
dual
target
reduc
toxic
better
complianc
along
enhanc
drug
efficaci
incorpor
drug
molecul
clay
miner
receiv
great
deal
attent
biomed
applic
claydrug
hybrid
distinguish
simpl
physic
mixtur
compon
variou
polar
cation
speci
combin
clay
miner
physic
adsorpt
intercal
form
claydrug
hybrid
materi
larg
ssa
cec
clay
miner
organ
drug
molecul
stabil
interlay
space
clay
miner
could
orient
monolay
bilay
pseudotripl
layer
paraffinlik
monolay
bilay
arrang
bergaya
lagali
depend
cec
clay
miner
also
amount
drug
load
result
controlledreleas
sustainedreleas
properti
abdelmohsen
et
al
takahashi
et
al
jung
et
al
lvov
et
al
joshi
et
al
addit
clay
miner
util
formul
addit
order
enhanc
solubl
poorli
solubl
drug
jung
et
al
dornela
et
al
lim
et
al
improv
photodispersiontherm
stabil
fragil
bioactiv
molecul
elnahh
et
al
cype
et
al
takahashi
et
al
pongjanyakul
et
al
provid
mucoadhes
properti
increas
retent
time
gastrointestin
gi
tract
preocular
surfac
dobrozsi
hua
et
al
salcedo
et
al
fascin
featur
claydrug
hybrid
materi
allow
potenti
develop
effici
dd
present
review
dd
claydrug
hybrid
materi
categor
base
method
administr
advantag
therapeut
effect
summar
challeng
futur
prospect
claydrug
hybrid
describ
term
biomed
applic
clay
miner
use
wide
ingredi
pharmaceut
formul
indic
us
food
drug
administr
fda
inact
ingredi
databas
tabl
exampl
na
form
sme
effect
lax
stimul
defec
osmosi
ca
form
use
antidiarrhea
agent
via
oral
administr
due
strong
adsorb
properti
alestig
et
al
ippol
carretero
addit
clay
miner
well
known
emulsifi
gell
thicken
agent
pharmaceut
formul
oral
medic
bolger
visera
pezgalindo
abend
lagali
clay
miner
absorb
water
oil
modul
viscos
formul
use
ingredi
improv
organolept
qualiti
pharmacolog
formul
clay
miner
mask
unpleas
tast
smell
drug
prevent
unwant
chang
intrins
color
physicochem
properti
stabil
effect
inorgan
matrix
modul
drugreleas
properti
lee
et
al
oh
et
al
ambrogi
et
al
clay
miner
also
employ
mani
year
dermatolog
protect
skin
extern
physic
chemic
substanc
palliat
joint
inflamm
cure
skin
diseas
ferrand
yvon
cara
et
al
cara
et
al
clay
miner
also
util
antibacteri
agent
wound
heal
clark
et
al
meng
et
al
william
haydel
wei
et
al
hsu
et
al
filler
fabric
transderm
patch
tan
pfister
strategi
develop
order
provid
good
adhes
skin
without
pain
damag
outermost
skin
layer
stratum
corneum
detach
remov
patch
hydrophil
properti
clay
miner
case
local
administr
clay
miner
bonerel
biomed
applic
novel
type
bonec
composit
consist
organomodifi
montmorillonit
omnt
poli
methyl
methacryl
pmma
report
wang
et
al
prepar
omnt
octadecylammonium
ion
intercal
interlay
space
mnt
ionexchang
reaction
way
hydrophob
mnt
could
establish
interlamellar
space
mnt
expand
space
increas
consider
nm
ion
exchang
reaction
indic
octadecylammonium
ion
enter
expand
interlay
space
clay
figur
well
order
second
third
order
peak
correspond
reflect
respect
observ
aqueou
suspens
wt
omnt
blend
biocompat
pmma
meltblend
process
isayev
palsul
xray
diffract
xrd
peak
observ
scan
rang
clay
content
composit
small
gener
suffici
diffract
intens
figur
hand
diffract
peak
composit
contain
wt
omnt
locat
correspond
valu
nm
entangl
polym
chain
pmma
insert
interlay
space
omnt
result
expans
space
compar
unalt
omnt
blend
time
increas
min
pronounc
exfoli
omnt
occur
gradual
rather
flat
small
hump
posit
figur
nanoscal
mix
establish
degre
interact
organ
inorgan
increas
result
extens
interfaci
contact
omntpmma
composit
prepar
show
signific
enhanc
term
thermal
stabil
without
degrad
pmma
also
signific
improv
mechan
properti
impact
strength
gener
desir
typic
formul
bone
cement
particular
thermal
degrad
temperatur
impact
strength
omntpmma
composit
increas
time
respect
compar
pure
pmma
addit
omntpmma
composit
show
improv
cell
growth
bonec
surfac
confirm
colorimetr
assay
assess
cell
metabol
activ
newli
design
bonec
composit
therefor
abl
meet
requir
orthoped
applic
biodegrad
polym
clay
composit
use
anticorros
coat
surfac
biocorrod
implant
devic
specif
stent
wittchow
gener
implant
stent
one
effect
treatment
vascular
diseas
offer
opportun
support
hollow
damag
organ
stent
made
corrod
magnesium
alloy
offer
limit
biomed
applic
rapid
degrad
physiolog
condit
biodegrad
polymerclay
composit
offer
promis
term
passiv
coat
layer
biocorrod
stent
aid
clay
miner
transmiss
rate
water
key
factor
term
passiv
coat
layer
reduc
dramat
transmissionr
valu
standard
water
vapor
gm
per
day
implant
devic
could
protect
degrad
biolog
condit
thank
polymerclay
composit
coat
recent
new
strategi
emerg
investig
potenti
clay
miner
inorgan
drug
carrier
uniqu
properti
biocompat
increas
solubl
adsorpt
mucoadhes
sustain
releas
target
figur
attempt
made
describ
dd
claydrug
hybrid
materi
depend
rout
administr
figur
mani
effort
made
develop
claydrug
hybrid
intercal
absorb
drug
molecul
clay
miner
oral
administ
dd
repres
dosag
form
oral
administr
albert
et
al
although
suspens
kaolinpectin
effect
total
amount
drug
absorpt
halftim
drug
absorpt
extend
factor
due
fact
drug
molecul
adsorb
kaolinpectin
could
releas
sustain
manner
similar
studi
halloysit
natur
occur
microtubular
aluminosil
could
encapsul
highli
watersolubl
drug
diltiazem
hcl
order
induc
sustain
drugreleas
properti
releas
diltiazem
hcl
examin
dissolut
test
ph
buffer
media
simul
condit
small
intestin
drug
releas
halloysit
retard
slightli
evid
larg
burst
effect
compar
unalt
diltiazem
hcl
highli
watersolubl
natur
drug
simpl
entrap
halloysit
meant
clay
adequ
sustainedreleas
properti
attempt
prolong
releas
diltazem
hcl
halloysit
situ
polymer
variou
alkylcyanoacryl
monom
drugload
halloysit
hybrid
nonaqu
solvent
carri
h
among
three
differ
formul
diltiazem
hclhalloysit
hybrid
coat
polyisobutyl
cyanoacryl
found
effect
show
reduc
initi
burst
effect
achiev
sustain
releas
releas
kinet
best
fit
squareroot
time
depend
polyisobutyl
cyanoacryl
ad
coat
surfac
drugencapsul
halloysit
situ
polymer
retard
drug
releas
significantli
anoth
approach
extend
drug
releas
made
use
kaolinit
halloysit
pellet
extrusionspheron
cryopellet
subsequ
drug
molecul
load
vacuum
impregn
techniqu
byrn
deasi
forsgren
et
al
drug
molecul
load
pellet
exhibit
prolongedreleas
profil
follow
initi
burst
releas
due
entrap
within
porou
architectur
pellet
pellet
porou
clay
oral
dosag
form
could
lead
extend
drug
releas
depend
ph
releas
medium
also
design
porou
architectur
includ
poros
pore
size
case
halloysit
pellet
drug
releas
prolong
due
entrap
drug
molecul
within
halloysit
microtubul
sever
attempt
also
made
develop
oral
administ
claydrug
hybrid
chemotherapi
gener
intact
form
chemotherapeut
agent
often
caus
advers
side
effect
due
nonsitespecif
adsorpt
bodi
order
reduc
perceiv
toxic
achiev
control
releas
colorect
cancer
therapi
hybrid
prepar
intercal
wt
initi
concentr
ph
h
mnt
lin
et
al
kevadiya
et
al
jin
et
al
total
load
amount
mnt
determin
mgg
mnt
prove
thermogravimetr
analysi
hybrid
expect
achiev
situ
releas
colorect
cancer
therapi
term
bioavail
oral
administ
anticanc
drug
attempt
made
dong
feng
develop
bioadhes
poli
llactidecoglycolid
montmorillonit
nanoparticl
plgamnt
np
base
emuls
solvent
evapor
method
np
formul
mnt
matrix
addit
materi
mnt
could
play
role
coemulsifi
synthesi
np
also
influenc
particl
morpholog
encapsul
effici
mucoadhes
mnt
enabl
mark
increas
cellular
uptak
effici
bare
plga
np
two
human
colonderiv
cell
line
cell
cell
depend
amount
mnt
fluorescentload
plgamnt
np
base
result
one
might
expect
increas
resid
time
drugload
plgamnt
np
gi
tract
mucu
epitheli
surfac
thu
promot
bioavail
oral
administ
anticanc
drug
work
plgamnt
np
sun
et
al
allow
advanc
target
drug
deliveri
surfac
decor
human
epiderm
growth
factor
antibodi
trastuzumab
breast
cancer
chemotherapi
multifunct
formul
reduc
advers
side
effect
model
anticanc
drug
employ
paclitaxel
pac
promot
synergist
therapeut
effect
achiev
target
deliveri
paclitaxelplgamnt
np
np
analyz
xray
photoelectron
spectroscopi
sodium
dodecyl
sulfat
polyacrylamid
gel
electrophoresi
analysi
evalu
presenc
stabil
trastuzumab
plga
np
respect
vitro
intern
two
differ
fluorescentload
plgamnt
np
without
antibodi
demonstr
surfacemodifi
np
display
much
greater
cellular
uptak
effici
breast
cancer
cell
express
fluoresc
strength
trastuzumab
decor
enhanc
cellular
uptak
breast
cancer
cell
known
posit
compar
therapeut
effect
commerci
avail
paclitaxel
agent
taxol
pacplgamnt
np
pacplgamnth
np
vitro
cytotox
assay
carri
cell
line
antibodydecor
np
show
therapeut
effect
time
greater
pacplga
mnt
np
taxol
respect
estim
level
half
maximum
inhibitori
concentr
ic
concentr
drug
requir
inhibit
vitro
h
incub
follow
plgamnt
np
studi
feng
et
al
introduc
datocopheryl
polyethylen
glycol
succin
tpg
watersolubl
deriv
natur
vitamin
e
form
esterif
vitamin
e
succin
polyethylen
glycol
peg
poli
lactid
montmorillonit
nanoparticl
plamnt
np
newli
design
tpgsplamnt
np
display
substanti
emulsif
effect
result
greater
drug
encapsul
effici
cellular
adhes
properti
without
target
effect
ic
valu
formul
tpgsplamnt
np
found
three
time
effect
term
therapeut
effect
human
breast
adenocarcinoma
cell
taxoter
use
clinic
addit
vivo
pharmacokinet
studi
normal
spraguedawley
rat
reveal
oral
administr
tpgsplamnt
np
achiev
halfliv
time
greater
improv
bioavail
factor
compar
taxoter
administ
intraven
inject
interestingli
singl
dose
np
formul
oral
medic
sustain
chemotherapeut
efficaci
week
compar
h
intraven
administ
taxoter
new
concept
relat
organolept
develop
clay
miner
emerg
pharmaceut
specif
tastemask
formul
clay
miner
block
unpleas
tast
drug
studi
intens
drug
often
face
limit
term
formul
design
poor
patient
complianc
sildenafil
sdn
aripiprazol
apz
intercal
mnt
cation
exchang
reaction
yield
claydrug
hybrid
subsequ
coat
cation
polym
polyvinylacet
diethylamino
acet
aea
spraydri
process
improv
tasteblock
effici
also
control
drugreleas
kinet
lee
et
al
oh
et
al
aeacoat
sdnmnt
apzmnt
hybrid
suppress
drugreleas
rate
signific
extent
sdn
apz
neutral
ph
min
suggest
potenti
mask
bitter
unpleas
tast
drug
buccal
caviti
simul
gastricfluid
condit
ph
releas
profil
sdn
sdnmnt
aeacoat
sdnmnt
examin
compar
intact
sdn
clinic
use
drug
viagra
figur
predict
intact
sdn
viagra
display
substanti
initi
burst
releas
sdn
within
min
cumul
releas
amount
reach
h
due
high
solubl
sdn
acid
condit
hand
sdn
could
releas
effect
sdnmnt
strong
ionic
interact
intercal
sdn
mnt
acid
condit
remark
sdn
discharg
aeacoat
sdnmnt
within
min
reach
h
dissolv
cation
aea
low
ph
exchang
sdn
interlay
space
mnt
enlarg
interlay
space
facilit
drug
diffus
toward
releas
media
regard
apz
drugreleas
rate
aeacoat
apzmnt
increas
significantli
help
aea
compar
apzmnt
figur
drugreleas
pattern
reveal
aeacoat
drugmnt
hybrid
consid
good
formul
prevent
unpleas
tast
drug
similar
drug
efficaci
altern
use
clinic
environ
addit
pharmaceut
formul
prove
use
improv
vivo
pharmacokinet
bioavail
verifi
comparison
drug
current
clinic
use
figur
aeacoat
hybrid
maximum
concentr
c
max
area
curv
h
infin
auc
larger
obtain
viagra
auc
mg
hml
c
max
mgml
case
aeacoat
hybrid
increas
vivo
drug
bioavail
shown
compar
vol
claydrug
hybrid
materi
biomed
applic
abilifi
claydrug
hybrid
coat
cation
macromolecul
demonstr
therefor
potenti
block
unpleas
tast
drug
well
enhanc
bioavail
drug
summari
clay
miner
benefit
featur
appli
wide
oral
dd
clay
miner
drug
deliveri
vehicl
play
import
role
term
enhanc
bioavail
drug
molecul
auc
area
plasma
concentrationtim
curv
infin
c
max
maximum
plasma
concentr
max
time
requir
reach
c
max
elimin
halflif
v
f
appar
volum
distribut
clf
total
clearanc
statist
signific
differ
p
role
function
characterist
claydrug
hybrid
increas
solubl
substanti
emulsif
effect
signific
encapsul
effici
controlledreleas
profil
manner
sustain
extend
releas
cell
adhes
cellular
uptak
effici
mucoadhes
block
unpleas
tast
drug
clay
miner
offer
promis
therefor
inorgan
biomateri
provid
novel
perspect
develop
oral
drug
deliveri
clay
miner
employ
pharmaceut
ingredi
drug
carrier
transderm
drug
deliveri
system
tdd
wokovich
et
al
kim
et
al
well
use
releas
drug
control
rate
system
circul
passiv
diffus
across
skin
tdd
allow
user
maintain
drug
concentr
plasma
within
therapeut
effect
level
extend
period
time
avoid
firstpass
metabol
liver
gi
tract
simpl
administr
noninvas
dosag
lead
improv
patient
complianc
termin
easili
point
remov
patch
type
dosag
form
final
type
dd
allow
selfmed
mani
relat
studi
tdd
reveal
main
factor
relat
skin
permeabl
drug
molecul
concentr
gradient
distribut
coeffici
diffus
coeffici
control
simpli
combin
clay
miner
particular
clay
miner
drugdeliveri
vehicl
enhanc
solubl
poorli
solubl
drug
drug
intercal
deintercal
interlay
space
clay
molecular
level
jung
et
al
park
et
al
ha
xantho
clay
miner
formul
mani
kind
dosag
form
powder
gel
cream
ointment
film
bandag
patch
transderm
administr
indomethacinmontmorillonit
idmmnt
complex
report
ito
et
al
effect
increas
skin
permeabl
drug
evalu
vitro
franz
cell
diffus
method
result
surpris
idm
idmmnt
complex
becam
almost
three
time
solubl
intact
form
due
stabil
idm
surfac
mnt
hydrogen
bond
molecular
arrang
poorli
solubl
idm
idmmnt
complex
prevent
recrystal
idm
hydrophil
surfac
complex
also
result
enhanc
dispers
complex
aqueou
solut
solubl
idm
therefor
stabil
mnt
amorph
form
greatli
improv
transderm
efficaci
idm
enhanc
one
exampl
transderm
drug
salicyl
acid
sa
incorpor
natur
bentonit
gradual
drug
releas
via
transderm
rout
bonina
et
al
note
clay
miner
employ
stabil
photounst
drug
ultraviolet
radiat
increas
drug
solubl
retard
releas
rate
use
franz
diffusioncel
method
aqueou
suspens
model
claydrug
hybrid
confirm
suppress
significantli
initi
burst
releas
sa
show
sustain
drugreleas
kinet
although
sa
adsorb
bentonit
penetr
skin
h
sustain
releas
behavior
model
hybrid
system
could
suitabl
real
transderm
applic
us
patent
applic
jo
et
al
newli
design
transderm
formul
disclos
claydrug
hybrid
piroxicam
pr
intercal
molecular
level
interlay
space
clay
miner
mix
adhes
polym
adsorpt
enhanc
transderm
patch
system
solubl
physicochem
stabil
well
dispers
pr
greatli
enhanc
combin
magnesium
aluminum
silic
ma
consequ
prevent
recrystal
drug
stabil
test
patch
contain
maspr
hybrid
store
acceler
condit
rel
humid
lightblock
state
permeabl
pr
patch
maintain
stabl
fashion
without
recrystal
even
month
storag
addit
permeabl
pr
patch
enhanc
factor
two
comparison
commerci
avail
trast
patch
even
though
claydrug
hybrid
patch
contain
half
amount
pr
claydrug
hybrid
materi
expect
promin
term
tdd
could
overcom
variou
intrins
demerit
intact
drug
could
also
confer
excel
skin
permeabl
drug
molecul
control
chemic
stabil
releas
behavior
drug
molecul
similar
approach
carri
chang
ph
synthet
medium
pongjanyakul
et
al
depend
ph
valu
drug
cation
anion
neutral
form
case
proton
cation
drug
ion
exchang
occur
neg
charg
clay
miner
exampl
nicotin
nct
volatil
alkalin
liquid
use
wide
smokingcess
therapi
possess
two
pk
valu
pk
pk
result
differ
charg
nct
differ
ph
condit
proton
nct
incorpor
ma
mixtur
mnt
saponit
sap
acid
ph
neutral
ph
condit
nct
encas
nctma
hybrid
becam
thermodynam
stabl
intact
form
nct
give
rise
reduct
evapor
differenti
scan
calorimetri
dsc
analysi
show
broad
endotherm
peak
evapor
nct
shift
intercal
nct
ma
addit
broad
exotherm
peak
observ
masnct
hybrid
due
decomposit
intercal
nct
vol
claydrug
hybrid
materi
biomed
applic
observ
dsc
thermogram
intact
nct
addit
nct
molecul
stabil
ma
releas
biphas
initi
burst
releas
occur
follow
slow
releas
releas
profil
well
fit
particl
diffusioncontrol
model
higuchi
model
singhvi
singh
specif
nct
releas
rapidli
physic
mixtur
nct
ma
within
min
releas
nct
masnct
hybrid
reduc
significantli
time
reach
nct
releas
valu
nct
releas
masnct
hybrid
eight
time
greater
physic
mixtur
masnct
hybrid
may
good
model
case
transderm
drug
deliveri
due
enhanc
thermal
stabil
sustain
releas
behavior
new
tdd
shaikh
et
al
suggest
incorpor
organomodifi
clay
oc
hybrid
polydimethyl
siloxan
pdm
attain
ocbas
pressur
sensit
adhes
psa
formul
ocpdm
hydrophob
surfac
properti
organomodifi
clay
miner
facilit
format
claypolym
composit
eventu
improv
mechan
properti
shear
strength
polym
composit
moreov
hydrophil
surfac
properti
pdm
adhes
termin
group
could
result
strong
hydrogen
bond
clay
platelet
give
rise
enhanc
dispers
aqueou
matrix
base
strategi
optim
level
oc
addit
polym
matrix
transderm
psa
formul
found
shaikh
et
al
realiz
control
drugreleas
kinet
enhanc
adhes
properti
reinforc
shear
strength
ad
oc
initi
burst
drug
releas
suppress
reason
well
consequ
total
drug
releas
decreas
day
respect
sure
due
fact
clay
platelet
well
dispers
psa
composit
result
control
releas
drug
molecul
addit
measur
shear
adhes
failur
temperatur
saft
shear
strength
present
signific
improv
adhes
properti
ocpdm
composit
saft
shear
strength
determin
enhanc
ocload
psa
composit
due
reinforc
effect
homogen
dispers
clay
miner
ocpsa
formul
would
applic
tdd
could
provid
steadi
extend
penetr
drug
blood
lead
minim
advers
side
effect
toxic
also
improv
adhes
properti
mechan
strength
sum
clay
miner
play
import
role
pharmaceut
ingredi
improv
adhes
mechan
properti
tdd
formul
also
transderm
drug
deliveri
carrier
enhanc
solubl
physicochem
stabil
dispers
drug
molecul
due
combin
drug
molecul
clay
miner
claydrug
hybrid
provid
steadi
prolong
penetr
drug
molecul
skin
controlledreleas
properti
result
improv
drug
efficaci
minim
side
effect
drug
claydrug
hybrid
could
suggest
therefor
promis
tdd
improv
drug
bioavail
mani
attempt
made
recent
decad
hubbel
khang
et
al
krisanapiboon
et
al
noel
et
al
bhattarai
et
al
develop
local
drug
deliveri
system
ldd
concept
examin
mainli
order
deliv
therapeut
agent
directli
desir
target
organ
andor
cell
decreas
concomit
secondari
system
complic
simultan
increas
drug
efficaci
compar
use
rout
dd
tsourvaka
claydrug
hybrid
suggest
promis
candid
ldd
reason
mention
also
due
featur
advantag
maintain
effect
concentr
drug
heal
minim
system
side
effect
posit
point
claydrug
hybrid
formul
confer
sustain
drugreleas
properti
could
reduc
frequenc
drug
administr
patient
complianc
dosag
form
clay
miner
local
administr
includ
film
tablet
buccal
drug
deliveri
local
inject
periodont
treatment
bone
cement
film
implant
devic
ocular
drug
deliveri
vagin
ring
stent
lidocain
ldc
use
wide
local
anesthet
due
low
toxic
rel
high
potenc
remedi
effect
ldc
last
min
rner
et
al
padula
et
al
order
prolong
medicin
effect
ldc
intercal
interlay
space
mnt
mean
ionexchang
reaction
acid
ph
abdelmohsen
et
al
ph
import
factor
influenc
interc
ionexchang
reaction
ldc
mnt
number
ionic
speci
ldc
chang
differ
ph
valu
optim
ldcmnt
hybrid
provid
longlast
local
anesthet
activ
ldc
sustainedreleas
kinet
nctabsorb
sodium
alginatemagnesium
aluminum
silic
sama
base
film
suggest
pongjanyakul
suksri
signific
potenti
use
buccal
deliveri
system
sama
film
prepar
load
larg
amount
nct
achiev
sustain
permeat
rate
compar
nativ
sa
film
acid
neutral
ph
proton
nct
molecul
could
strongli
bound
neg
charg
film
electrostat
interact
incorpor
ma
mixtur
mnt
sap
sa
film
ph
increas
nct
content
film
ww
decreas
nct
permeat
rate
cm
min
compar
sa
film
nctload
sama
film
fabric
ph
ph
show
greater
load
nct
respect
smaller
permeat
rate
cm
min
respect
nctload
sama
film
prepar
ph
hand
detach
forc
nctload
sama
film
reduc
significantli
regardless
prepar
ph
compar
sa
film
interact
ma
hydroxyl
andor
carboxyl
group
sa
result
low
water
uptak
swell
composit
film
decreas
mobil
flexibl
sa
molecul
eventu
reduc
physic
entangl
sa
mucu
although
nctload
sama
film
show
weaker
bioadhes
properti
nctload
sa
film
clay
mineralload
film
still
bioadhes
enough
adhes
mucos
membran
given
result
buccal
drug
deliveri
formul
clay
miner
could
expect
suppress
intrins
volatil
nct
enhanc
bioavail
nct
appli
mucos
membran
one
interest
biomed
applic
claydrug
hybrid
would
probabl
implant
materi
drugdeliveri
function
implant
materi
could
deliv
activ
ingredi
specif
organ
teeth
bone
subcutan
fat
eye
vagina
blood
vessel
local
drugdeliveri
formul
envis
kelli
et
al
periodont
diseas
use
two
compon
chitosantetracyclinehalloysit
hybrid
prepar
formul
thermorespons
polym
poloxam
tissu
adhes
polyethylen
glycol
peg
octyl
cyanoacryl
oca
water
improv
retent
gingiv
periodont
pocket
defin
presenc
abnorm
depth
gingiv
sulcu
gingiv
tissu
contact
tooth
optim
formul
poloxam
ww
peg
ww
oca
ww
mgml
chitosantetracyclinehalloysit
hybrid
determin
care
denatur
test
syring
facilit
eas
administr
periodont
pocket
well
thermal
stabil
maintain
high
storag
modulu
upon
achiev
bodi
temperatur
formul
stabl
vitro
least
month
room
temperatur
chang
syring
n
gell
temperatur
preliminari
vivo
test
use
wound
pocket
creation
model
dog
carri
estim
amount
drug
releas
retent
abil
formul
drug
found
deliv
easili
target
site
local
effect
level
averag
drug
concentr
mg
retain
pocket
week
order
treat
chronic
inflammatori
diseas
claydrug
hybridbas
polyurethan
pu
implant
develop
da
silva
et
al
pinto
et
al
biodegrad
pu
investig
extens
due
great
biocompat
chemic
versatil
superior
mechan
properti
da
silva
et
al
incorpor
wt
mnt
aqueou
polyurethan
dispers
pud
order
control
biodegrad
pud
releas
rate
drug
incorpor
disctyp
implant
devic
mm
thick
mm
diamet
fabric
success
cast
pud
composit
contain
dexamethason
acet
act
mnt
implant
subcutan
fat
back
mice
examin
vivo
drug
releas
rate
biocompat
prior
vivo
evalu
vitro
degrad
pud
pudmnt
composit
vitro
releas
profil
act
actload
pud
pudmnt
composit
analyz
increas
mass
loss
pudmnt
composit
associ
greater
hydrophil
pud
clay
miner
incorpor
hydrophil
mnt
effect
allow
penetr
diffus
water
polym
chain
increas
hydrolysi
rate
ester
bond
pcl
segment
pud
composit
vitro
drugreleas
test
show
act
releas
first
week
pud
pudmnt
composit
respect
diffus
process
preexist
channel
pore
releas
rate
enhanc
significantli
hydrolyt
degrad
pud
pudmnt
composit
th
th
week
dissolut
test
final
stage
releas
slower
releas
rate
act
observ
pud
pudmnt
composit
consequ
reduc
drug
concentr
implant
disc
given
posit
result
incorpor
clay
miner
appear
advantag
term
achiev
control
longterm
drug
deliveri
implant
devic
moreov
mild
inflammatori
respons
observ
tissu
adjac
implant
initi
state
resolv
complet
within
period
extent
neutrophil
accumul
assess
myeloperoxidas
mpo
activ
decreas
substanti
first
week
implant
period
indic
inflammatori
respons
resolv
quickli
pu
implant
fabric
claydrug
hybrid
thu
seem
feasibl
local
drug
deliveri
devic
treatment
chronic
inflammatori
diseas
extens
advanc
claydrugpolym
composit
implant
devic
da
investig
ocular
implant
posterior
segment
ocular
diseas
uveiti
inflamm
uvea
kind
diseas
cure
easili
mean
topic
eye
drop
oral
drug
medic
administr
medic
allow
effect
penetr
drug
natur
barrier
bodi
attempt
made
immobil
dexamethason
acet
type
corticoid
use
treatment
uveiti
biodegrad
pu
composit
vol
claydrug
hybrid
materi
biomed
applic
contain
clay
miner
obtain
delamin
mnt
within
pu
aqueou
dispers
mnt
employ
adjust
mechan
properti
pu
match
ocular
soft
tissu
elast
modulu
intact
pu
improv
factor
addit
mnt
could
achiev
easili
simpli
chang
ratio
soft
hard
segment
pu
addit
well
distribut
mnt
pu
composit
play
import
role
reservoir
transport
therapeut
ingredi
desir
site
may
contribut
greatli
overcom
low
permeabl
drug
thu
drug
releas
constantli
pucontain
mnt
day
diffus
togeth
degrad
mechan
pu
final
evalu
vitro
cytotox
composit
human
retin
pigment
epitheli
cell
cultur
directli
pu
pumnt
implant
day
mtt
bromid
tetrazolium
assay
conduct
assess
cell
metabol
activ
cellular
oxidoreductas
enzym
viabl
cell
abl
reduc
convert
mtt
purpl
tablet
ointment
cream
singer
color
formazan
marker
viabl
cell
viabil
cell
upon
cultur
pu
pumnt
confirm
respect
compar
neg
control
experiment
result
indic
biocompat
dexamethason
acetateload
pumnt
composit
could
applic
suitabl
substrat
ocular
implant
devic
synthesi
character
hydrogel
contain
polyacrylamidesodium
carboxymethyl
cellulosemnt
nanocomposit
attempt
sharifzadeh
order
fabric
vagin
ring
ldd
ad
sodium
carboxymethyl
cellulos
hydrogel
swell
behavior
improv
gradual
mechan
strength
reduc
resolv
defect
mnt
ad
hydrogel
rigid
structur
optimum
swell
properti
aid
mnt
extend
drug
releas
achiev
day
simul
local
condit
reduc
initi
burst
drug
composit
contain
clay
miner
may
possibl
candid
vagin
dd
briefli
claydrug
hybrid
could
formul
mani
differ
type
dosag
form
ldd
properti
featur
desir
site
drug
could
deliv
directli
achiev
effect
drug
concentr
long
time
minim
system
side
effect
drug
accompani
sustain
releas
properti
claydrug
hybrid
local
administ
claydrug
hybrid
allow
user
reduc
frequenc
medicin
deliveri
increas
patient
complianc
regard
clay
miner
formul
addit
drug
carrier
appli
varieti
rout
includ
oral
transderm
local
administr
tabl
depend
rout
administr
clay
miner
biomed
applic
clay
miner
select
order
control
key
paramet
includ
size
swellabl
cec
ssa
mucoadhes
dispers
drugreleas
rate
addit
hybrid
reaction
drug
clay
miner
whatev
physic
adsorpt
intercal
result
enhanc
solubl
physicochem
stabil
drug
molecul
also
offer
control
sustain
drugreleas
rate
eventu
achiev
improv
bioavail
due
effici
drug
deliveri
advanc
develop
claydrug
hybrid
system
via
variou
rout
administr
allow
medic
deploy
specif
target
part
bodi
organ
cell
although
field
claydrug
hybrid
system
experienc
signific
growth
past
decad
mani
challeng
remain
gener
prospect
claydrug
hybrid
system
seem
effect
work
well
vitro
fail
vivo
due
complic
involv
real
biolog
condit
also
toxicolog
studi
requir
determin
whether
claydrug
hybrid
polymerclaydrug
composit
appli
clinic
environ
gene
deliveri
program
dd
ie
target
andor
environment
stimuli
respons
clay
miner
challeng
innov
design
term
formul
claydrug
hybrid
advanc
clinic
use
consequ
open
new
drugdeliveri
market
final
research
clay
miner
expand
applic
biomed
field
regen
tissu
engin
theranosi
person
medicin
pharmaceut
implant
etc
